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Abstract 
Astrocytes have essential roles in the central nervous system and are also implicated in the 
pathogenesis of neurodegenerative disease. Forming non-overlapping domains, astrocytes are highly 
complex cells. Immunohistochemistry to a variety of proteins can be used to study astrocytes in tissue, 
labelling different cellular components and subpopulations, including GFAP, ALDH1L1, CD44, 
NDRG2 and amino acid transporters, but none of these label the entire astrocyte population. 
Increasing heterogeneity is recognised in the astrocyte population, a complexity that is relevant both 
to their normal function and pathogenic roles. They are involved in neuronal support, as active 
components of the tripartite synapse and in cell interactions within the neurovascular unit, where they 
are essential for blood brain barrier maintenance and neurovascular coupling. Astrocytes change with 
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age, and their responses may modulate the cellular effects of neurodegenerative pathologies, which 
alone do not explain all of the variance in statistical models of neurodegenerative dementias. 
Astrocytes respond to both the neurofibrillary tangles and plaques of Alzheimer’s disease, to 
hyperphosphorylated tau and Aȕ, eliciting an effect which may be neuroprotective or deleterious. 
Astrocyte hypertrophy, in the form of gliosis, occurs, but also astrocyte injury and atrophy. Loss of 
normal astrocyte functions may contribute to reduced support for neurons and dysfunction of the 
neurovascular unit. Understanding how astrocytes contribute to dementia requires an understanding of 
the underlying heterogeneity of astrocyte populations, and the complexity of their responses to 
pathology. Enhancing the supportive and neuroprotective components of the astrocyte response has 
potential translational applications in therapeutic approaches to dementia.  
 
Abbreviations:  AΆ Beta-amyloid; AD Alzheimer’s disease; ALDH1L1 aldehyde dehydrogenase 1 
family member L1; ARTAG aging related tau astrogliopathy; BBB blood brain barrier; CAA cerebral 
amyloid angiopathy; CBF cerebral blood flow; CFAS Cognitive Function and Ageing Study; CNS 
central nervous system; CLU clusterin; CR1 complement receptor 1; EAAT excitatory amino acid 
transporter; EGFP – enhanced green fluorescent protein; ET-1 Endothelin-1; FTD frontotemporal 
dementia; GFAP glial fibrillary acidic protein; GLAST glutamate/aspartate transporter; GLT-1 
glutamate transporter-1; GWAS genome-wide association studies; MND Motor Neurone Disease; 
NDRG-2 N-myc downregulated gene 2; NFT neurofibrillary tangle; NVU Neurovascular unit; SASP 
senescence associated secretory phenotype; SOD-1 superoxide dismutase-1; TREM2 triggering 
receptor expressed on myeloid cells 2 
 
Astrocytes in the Context of Dementia Research 
The neuron is the target for many of the cellular pathologies of dementia, such as neurofibrillary 
tangles (NFTs) and Lewy bodies, whilst extracellular beta-amyloid (AΆ) may also target neurons and 
their processes. These classical pathologies remain central to theories of dementia pathogenesis and to 
neuropathological diagnosis, and much of the focus in dementia research has been on the neuron. 
However, although important correlates of dementia, other factors may also be important. Population 
based studies such as the UK Medical Research Council Cognitive Function and Ageing Study 
(CFAS), and other large autopsy series, have shown that classical neuropathological lesions alone do 
not account for all of dementia in statistical models, particularly at the oldest ages (1-8). This is also 
recognised in clinical trials with the identification of individuals with Alzheimer’s Disease (AD)-like 
clinical presentations but with little pathology on amyloid imaging or on neuropathology, so-called 
AD with insufficient neuropathology (9).  Different molecular forms of amyloid, tau and other protein 
pathologies are important on-going areas of therapeutic targets, but other factors may contribute to 
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age-related cognitive decline either independently or by modulating the effect of the classical cellular 
and molecular pathologies on neuronal fate and function. This includes other cell types and the 
interactions between them.  
 
Neurons function within the context of other cell types, and recent theories have emphasised the 
importance of dysfunction of the neurovascular unit (NVU) in ageing and in development of 
neurodegeneration and dementia (10, 11). The NVU includes the neuron, the microvasculature 
composed of endothelial cells and pericytes, astrocytes and the blood brain barrier (BBB). 
Oligodendrocytes and microglia are additional key components. A neurovascular hypothesis of 
dementia would then seek to integrate changes in the neuron with alterations of other cell types and 
their interaction within the NVU.  
 
Long thought of as “just” a supporting cell, or brain glue, the astrocyte has important physiological 
roles in relation to the neuron, to synaptic function, and to blood brain barrier and neurovascular 
coupling. Astrocyte dysfunction may therefore be an important contributor to dysfunction of the 
NVU, with effects on neurons and microvasculature. This review is focused on the role of the 
astrocyte in the brain and how perturbation of its function may contribute to dementia pathogenesis, 
particularly focusing on AD.  
 
Astrocyte Biology 
 
Classification  
Astrocytes were first described by Virchow in 1846 and were originally thought to be a homogenous 
population of cells which function to support neurons. The term ‘astrocyte’ was first used in 1893 by 
Michael von Lenhossek and refers to the stellate morphology of the cells (12).  There has been much 
debate around what constitutes an astrocyte given the diversity of this cell type and the commonalities 
with other cell types of the central nervous system (CNS). A review by Kimelberg et al., sets out the 
following criteria for defining this cell type : 1) Nonexcitability; 2) A very negative membrane 
potential which is determined by the K+ gradient; 3) Glutamate and GABA uptake by astrocyte-
specific transporters; 4) the presence of intermediate filament bundles; 5) the presence of glycogen 
granules; 6) cell processes surrounding blood vessels and synapses; 7) the presence of gap junctions 
formed from connexins (13).   
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Astrocytes have been classified into two major morphological groups on the basis on their 
morphology and anatomical location; the fibrous astrocytes of the white matter and the protoplasmic 
astrocytes of the grey matter.  They have distinct morphologies, initially identified through the use of 
Golgi staining, with protoplasmic astrocytes having a more complex structure, with many finely 
branching processes (12).  Although both Golgi staining and immunolabelling of protoplasmic 
astrocytes have provided insights into the structure of these cells it is estimated that they reveal only a 
small proportion of total astrocyte volume. Immunohistochemistry for glial fibrillary acidic protein 
(GFAP), a structural protein found only in the main branches of the astrocyte, has been estimated to 
identify around 15% of the cell.  Die injection studies enable a larger proportion of the total astrocyte 
volume to be revealed, and have identified that protoplasmic astrocytes organise themselves into 
distinct domains with no overlap apparent (14).  The significance of these domains is not well 
understood but they are functional territories with autonomous features that are thought to be central 
to the astrocytes ability to coordinate synaptic activity and blood flow (12, 15).   Fibrous astrocytes 
send out long processes which are less elaborate than their grey matter counterparts.  These processes 
contact axons at nodes of Ranvier as well as establishing perivascular end-feet.  Fibrous astrocytes are 
organised along white matter tracts and unlike protoplasmic astrocytes do not organise themselves 
into domains.   
 
This binary classification, however, is an oversimplification. Several morphological types can be 
recognised in human cortex and are more complex than those found in other animals, such as rodents, 
that are often used for disease modelling. For example, the interlaminar astrocyte, which is found in 
superficial cortex with long processes extending into cortex, is unique to higher primates (16, 17). 
Much of the complexity of human brain is thought to arise from this phylogenetic evolution of 
astrocytes. Functional complexity is also being recognised but, as yet, has not been accounted for in 
neurodegeneration research.  
 
Developmental origin 
There are three distinct pools of glial progenitors in the cerebral cortex, radial cells of the ventricular 
zone, postnatal glial progenitor cells of the subventricular zone (SVZ) and glial restricted precursors.  
The protoplasmic astrocytes of the grey matter are mostly generated by embryonic radial glia whereas 
the fibrous astrocytes of the white matter are derived from neonatal SVZ progenitors (18).  It is 
generally accepted that astrocytes develop after neurons in the developing central nervous system 
although in spite of this they are thought to play a role in guiding axon migration and synaptic pruning 
(19)  Further, astrocyte-like cells residing in the adult subventricular zone can function as multi-potent 
stem cells in vivo and are the major source of adult neurogenesis in the olfactory bulb and 
hippocampus (20, 21).  However, it is important to consider that the developmental origins of 
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astrocytes are fundamentally different across species, suggesting that the contributions of astrocytes to 
the functioning CNS also differ across species (22).   
 
Glial Fibrillary Acidic Protein 
Since their initial classification numerous techniques have been used to further investigate astrocyte 
morphology and phenotype including immunohistochemical techniques.  GFAP is the prototypical 
marker for identifying astrocytes immunohistochemically.  GFAP is a class III intermediate filament 
protein, encoded by a gene on chromosome 17q21. There are several isoforms, including GFAP-Į, 
which is the main isoform in the CNS, and GFAP-į, which is particularly expressed by neurogenic 
subventricular astrocytes. A single nucleotide frameshift produces GFAP+1 variants that are 
expressed in a subset of astrocytes (23). Mutation in GFAP produces Alexander disease, a primary 
astrogliopathy characterised by Rosenthal fibre accumulation (24). 
 
GFAP expression increases with age in animal models, in which oxidative stress may play a role (25). 
It is also upregulated non-specifically under pathological conditions in the hypertrophic response of 
(astro)gliosis. This is a complex phenomenon, reflecting a spectrum of changes, from up-regulation of 
GFAP, increasing GFAP with proliferation and loss of domain structure through to compact glial scar 
formation with disruption of tissue architecture  (26). The term isomorphic gliosis has been used 
where gliosis does not disrupt the underlying cytoarchicture of the brain, so that remodelling of 
neuronal networks is permitted, whereas the term anisomorphic gliosis has been used where a 
permanent glial scar disrupts tissue architecture, preventing remodelling (27).  
 
GFAP up-regulation, detectable by immunohistochemistry, is a reliable marker for identifying 
reactive astrocytes, but astrogliosis also involves up-regulation of other intermediate filament 
proteins, namely vimentin, nestin and synemin (28, 29). Although astrogliosis appears to be a 
stereotypic reaction histologically, transcriptomic analysis shows that the pattern of gene expression 
within reactive astrocytes varies according to the stimulus, which is relevant to the functional role that 
astrocytes are likely to play in different pathological states (30). 
 
Astrocytes in the neurovascular unit 
The main areas of astrocyte function are summarised in Figure 2. Protoplasmic astrocytes form 
extensive contacts with blood vessels and the microvasculature and play a central role in regulating 
blood flow in the brain.  They release prostaglandins, nitric oxide and arachidonic acid in order to 
cause vasoconstriction or vasodilation of blood vessels, often in response to changes in synaptic 
activity. They have a role in neurovascular coupling, by which local cerebral blood flow is matched to 
neuronal activity and energy requirements (31).  In addition to effects on vasculature from neurons 
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themselves, astrocytes appear to be able to mediate both vasoconstriction and vasodilation. Changes 
in astrocyte intracellular calcium with activity lead to formation of arachidonic acid and release of 
vasoactive substances. Although incompletely understood, astrocyte responses may contribute to 
changes in functional MRI signals and these responses may be altered in ageing and CNS disease 
states.  
 
Close apposition of astrocytic end-feet with the vasculature is important in the induction and 
maintenance of the BBB (32).  In vitro studies have demonstrated that astrocytes can induce barrier 
properties in cerebral endothelial cells and it has been shown in vivo that loss of GFAP-
positive astrocytes from the inferior colliculus of rat brain is accompanied by widespread loss of the 
tight junctional proteins claudin-5, occludin and ZO-1 (33, 34). Perivascular astrocytes are also vital 
for ionic and water homeostasis.  Their end-feet are enriched in potassium channels, important for the 
spatial buffering of K+ in the extracellular space, whilst water movement through aquaporin-4 
channels is essential to osmotic balance (35).  
 
The tripartite synapse and astrocyte signalling 
Astrocytes have been shown to regulate the stability, dynamics, and maturation of dendritic spines 
(36, 37) and take part in the regulation of synaptic plasticity and synaptic transmission (38). The 
tripartite synapse was a phrase coined 16 years ago (39) to define the close proximity of astrocyte 
processes to pre- and post-synaptic neuronal elements (40) (Figure 2). This strategic positioning of 
astrocytes enables an interactive dialogue to occur between these two cell types which is central to the 
local and widespread communication of information across the brain.  
The exchange begins with the release of neurotransmitters from the pre-synaptic cleft, which triggers 
activation of metabotropic or ionotropic receptors on the astrocyte cell surface. Neuronally released 
transmitters such as glutamate, noradrenaline, histamine and acetylcholine are all capable of binding 
to receptors on the surface of astrocytes, which leads to a transient increase in calcium levels within 
the cell, the extent of which is dependent on the intensity of synaptic activity. In rat brain a single 
hippocampal astrocyte is estimated to be associated with approximately140000 hippocampal synapses 
(41) meaning that the processes of one astrocyte are in close proximity to a number of stimuli of 
differing intensities. Astrocytes integrate external synaptic activity and generate a calcium wave of 
corresponding magnitude that can exist in the small microdomain of a process or propagate 
throughout the cell. More recently it has been shown that calcium signalling in astrocytic processes 
can occur independently of signalling in the cell body, and this can compartmentalise neuronal 
activity to a specific region of the astrocyte (42). Calcium waves are not restricted to one astrocyte 
and can propagate via gap junctions to neighbouring astrocytes. Importantly, calcium oscillations in 
astrocytes are not just a chemical conversion of synaptic activity but can occur spontaneously and 
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excite neighbouring neurons (43).  
In response to neuronal activity astrocytes produce gliotransmitters to facilitate communication 
between neurons.  Gliotransmitter release occurs via a number of different mechanisms; calcium 
dependent exocytosis (44), non-exocytotic release from cytosolic pools; and calcium-independent 
channel mediated release. The molecular mechanisms that regulate the release of these neuroactive 
molecules (e.g glutamate, adenosine, GABA, ATP and D-serine) is  not fully understood but is 
thought to be predominantly controlled by calcium (45). Astrocytic release of gliotransmitters offers 
multiple ways of controlling synaptic activity as  astrocytes are able to selectively release a range of 
different gliotransmitters to individual synaptic inputs, each one having different mechanisms of 
action at  the pre or post-synaptic neuronal elements (46). In addition gliotransmitters interact with 
other cell types in the vicinity such as microglia and vascular cells.  
Astrocytes can further regulate signalling in the brain via the efficient removal of synaptically 
released inhibitory and excitatory neurotransmitters respectively known as ࢢ-aminobutyrate (GABA) 
and glutamate, which are taken up through transporters on perisynaptic astrocytic processes (47). 
Astrocytes can directly convert glutamate to glutamine (48) which upon release from the astrocyte is 
used by neurons to replenish  intracellular stores of glutamate and GABA.  Uptake of glutamate is 
also important for astrocytic amino acid metabolism. The speed astrocytes clear neurotransmitters 
from the synaptic cleft affects the level of post-synaptic activation (49). Thus activity at the synapse 
can be regulated by both the release and uptake of neuroactive molecules, and activity at a single 
synapse can quickly lead to ripples of bidirectional chemical crosstalk between a network of 
astrocytes and neurons. 
Finally, astrocytes are also capable of simultaneously integrating information beyond the synapse, 
such as from vascular cells and microglia, which allows them to finely tune the complex neuronal 
circuitry within a dynamic microenvironment. Astrocytes form networks, connected via gap junctions, 
which include connexins, which add a further layer to the integration of astrocytic and neuronal 
function (50). 
 
Astrocyte metabolism and neuronal support 
Astrocyte support in the form of neurotransmitter recycling, provision of energy substrates and 
cholesterol are important mechanisms by which astrocytes support the viability and function of 
neurons (Figure 2). Such astrocyte metabolic activities are important in astrocyte involvement in 
memory and learning (51) and the positioning of these cells means they are able to provide glucose 
and other molecules for neuronal metabolism, and to sense changes in neural activity in order 
to facilitate this. Astrocytes are known to avidly take up glucose and typically present a high 
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glycolytic rate (52) and the metabolic needs of active neurons are at least partly met by non-
oxidative glucose metabolism. The astrocyte-neuron lactate shuttle hypothesis proposes that 
astrocytes metabolise glucose to lactate which is then taken up by neurons and used as a fuel source 
(53).   In addition to this proposed function, astrocytes also store glucose in the form of glycogen 
which can act as a short-term energy buffer during periods of high neuronal activity, for example 
during learning and memory when astrocytic glycogen can be used to liberate lactate as an energy 
substrate for neurons (54, 55).  Astrocyte cholesterol metabolism is a further important area. 
Cholesterol is essential for normal brain function, including synaptic and receptor function. 
Astrocytes are the main source for neuronal cholesterol, via the APOE lipoproteins (56, 57).  
 
Cytopathology of Astrocytes in Ageing and Neurodegeneration 
 
Identifying astrocytes in tissue-based studies 
Many neuropathological studies of astrocytes have relied on the use of GFAP to detect these cells. 
However, many healthy astrocytes do not express detectable levels of GFAP, and expression of GFAP 
can depend upon the anatomical location of astrocytes as well as the species in which GFAP 
expression is being examined (26).   This can skew studies into the role of astrocytes in disease as 
only the population with up-regulated GFAP, reflecting the more reactive cells, is detected. This 
limitation of current detection methods should be kept in mind when interpreting the results of 
pathological studies. Thus, although GFAP might still be considered the ‘gold standard’ astrocyte 
marker there is a need for additional tissue markers to better capture the full spectrum of astrocytic 
cells. A number of other potential markers are available and can be used on human post mortem tissue 
(Figure 1). 
1.  S100ȕ marks many astrocytes, but is non-specific, labelling many other neuroglial cells (58-60).  
2. The excitatory amino acid transporters (EAATs), involved in glutamate uptake from the synaptic 
cleft. There are 5 types of EAAT in human brain with EAAT1 and EAAT-2 primarily expressed by 
astrocytes (61). The rodent analogues of these are designated GLAST (glutamate/aspartate 
transporter) and GLT-1 (glutamate transporter-1) respectively. Double labelling shows that EAAT-2 
and GFAP do not entirely overlap, so that there are EAAT2+/GFAP+, EAAT2+/GFAP- and EAAT2-
/GFAP+ populations (62). 
3. Glutamine synthetase is expressed in cell bodies and processes of astrocytes throughout the cortex 
(63). 
4.  CD44 is a cell surface glycoprotein that is a receptor for hyaluronic acid and may act as an 
adhesion molecule for astrocytes. This marker appears to be distributed more to processes in 
astrocytes and to identify particular subsets (64).  
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5. ALDH1L1 (aldehyde dehydrogenase 1 family, member L1, an enzyme involved in folate 
metabolism) is a marker identified from transcriptomic analysis of astrocytes. ALDH1L1 
immunohistochemistry labels astrocyte cell bodies and processes and appears to label more astrocytes 
than GFAP (65). In our hands, ALDH1L1 immunohistochemistry also labels oligodendrocytes. In 
mice, it is expressed in cortical and spinal astrocytes and studies in the G93A mutant SOD1 
(superoxide dismutase 1) motor neuron disease model suggest that it is upregulated in chronic 
neurodegeneration. These authors also showed that the gene expression profiles of ALDH1L1+  and 
GLT-1+ cells are similar, suggesting that they share astroglial identity (66).    
6. NDRG2 (N-myc downregulated gene 2) is expressed in the cell bodies and processes of astrocytes 
in humans and rodents. It appears to be involved in responses to stress but is downregulated in 
reactive astrocytes near a cortical glial scar. It has been suggested that NDRG2 may be a marker for 
mature non-reactive astrocytes (67, 68).  
 
In summary, there are a number of astrocytic markers in addition to GFAP, which show varying 
labelling patterns. To date, ALDHL1 and NDRG2 hold out the best promise for general markers that 
pick up the largest proportion of the astrocyte population. However, some of these markers require 
further validation in human tissue and whilst they provide options for the analysis of astrocytes, 
cannot be considered a universal marker; considerations of astrocyte heterogeneity and 
subpopulations will still be required.  
 
Astrocytes in ageing 
Ageing is the leading risk factor for the common dementias, including AD, dementia with Lewy 
bodies and vascular dementia.. Whilst age may operate partly via development of the classical 
neurodegenerative and vascular pathologies, age-related mechanisms may impair cells of the brain via 
a number of mechanisms (69) which could damage NVU function to act independently or in concert 
with classical neuropathologies. Astrocytes are affected by ageing, potentially impairing their 
complex functions or biasing their response to pathology to a less advantageous pattern.  
 
GFAP mRNA and protein levels appears to increase with ageing in rodents and humans, accompanied 
(in some studies) by S100ȕ (25, 70-72). Astrocytes in the ageing brain show features of senescence 
and expression of a senescence associated secretory phenotype (SASP). Transcriptomic studies also 
suggest a shift to a more proinflammatory phenotype in astrocytes with ageing (73-75) . These age-
related astrocytic changes might contribute to declining brain function via loss of function and 
neuroinflammation, and contribute to the background in which neurodegenerative disease develops. 
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Astrocytic inclusions 
AD is generally not associated with astroglial inclusions. However, tau positive thorny astrocytes are 
a feature of brain ageing (76, 77) . These are found particularly in subpial, subependymal and 
perivascular locations, particularly in mesial temporal structures and around brainstem. The inclusions 
may be Gallyas positive, suggesting that some of the tau is fibrillar, and immunohistochemical studies 
suggest that the inclusions are of 4-repeat tau. The significance and origin of these is currently 
uncertain, but they do not appear to be associated with dementia and studies have found either no, or a 
weak association with AD neuropathology. Those in a subpial location, however, are associated with 
subpial tau positive neuritic processes (78). Whether the astrocytes derive the tau from neuronally 
produce phospho-tau is currently unknown. Recently a consensus approach has been developed for 
assessment of the age related form of tau, which also includes “astrocytes with finely granular (tau) 
immunoreactivity in processes”, under an umbrella term of Aging Related Tau Astrogliopathy 
(ARTAG) (79). 
 
Astrocytes in Alzheimer’s disease 
The initial observation that astrocytes appeared ‘activated’ in AD brain was thought to be a secondary 
and non-specific response to the disease process (80), and a neurocentric view has predominated in 
AD and neurodegeneration research generally. However, astrocytes are central to pathogenic 
mechanisms in neurodegeneration. This may include toxic gains-of-function, such as production of 
cytokines and chemokines, or loss of their complex physiological functions, such as neuronal support 
(e.g. neurotransmitter recycling, energy substrate provision) and spatial buffering (e.g. K+, H+) (26). 
Essential to synaptic maintenance, disruption of the normal glio-neuronal interaction can lead to 
synaptic dysfunction and contribute to cognitive impairment (81). Studies in Motor Neurone Disease 
(MND) have shown that astrocytes affect disease progression (82-84), giving rise to a non-cell-
autonomous theory of MND, and establishing the principle that astrocytes have a deterministic role in 
pathogenic progression of a neurodegenerative disease.  
The astrocytic response to beta-amyloid 
The first clear evidence that astrocytes play an active role in the AD process was provided by Wyss-
Corey et al., (2003) who showed that astrocytes were able to uptake and degrade Aȕ using an in vitro 
system of cultured mouse astrocytes (85). However, this was not the first evidence for the uptake of 
Aȕ by astrocytes since earlier studies had shown the presence of Aȕ-containing astrocytes (86, 87). 
Astrocytes respond to plaques, along with microglia and their activation is important in pathogenesis.   
Since they can take up Aȕ they are involved in plaque progression, with death of Aȕ loaded astrocytes 
giving rise to secondary plaques (88).  
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The mechanisms governing the receptor-mediated uptake of AΆ are not fully understood, particularly 
whether the uptake of AΆ induces a change in astrocyte phenotype which alters their usual neuro-
supportive function.  One receptor identified as being involved in uptake and clearance of Aȕ is the 
Low density lipoprotein receptor-related protein 1 (LRP1) (89, 90).  LRP1 is also a receptor for the 
uptake of apoE and complexes of apoE-AΆ and highlights  the importance of this receptor, as well as 
apoE, in astrocytic clearance of AΆ (91).  However, it is possible that a number of as yet unidentified 
receptors are also involved in Aȕ uptake. 
 
Whether the response of astrocytes to Aȕ is a protective mechanism or results in further damage is 
not clear with conflicting evidence which likely reflects differences in experimental approach, 
although it is worth considering that there may be an impact of age on the ability of astrocytes to 
uptake and degrade Aȕ effectively.  Evidence from cell culture models of AD suggest that the 
astrocyte response to Aȕ actively contributes to the disease process; Garwood et al. (2011) have 
shown that the toxic properties of Aȕ are enhanced in cultures of primary neurons with small 
contaminating numbers of astrocytes and that changes in tau phosphorylation and cleavage are only 
observed in the presence of astrocytes (92).  This toxicity is associated with a distinct astrocytic 
inflammatory profile which might, amongst other things, increase the amyloidogenic processing of 
APP in astrocytes (93).  This same paper has evidence showing Aȕ1-42 itself can further increase 
astrocytic BACE1, APP and ȕ-secretase processing resulting in further increases in oligomeric and 
fibrillary Aȕ, providing evidence astrocytes contribute to the production, as well as the degradation, 
of Aȕ. 
 
Astrocytes and neuroinflammation in AD 
Neuroinflammation is a prominent and early feature of AD which plays a key role in modulating the 
progression of disease via a range of inflammatory mediators and neurotoxic compounds.  Genome-
wide association studies (GWAS) have identified several immune-associated genes that are associated 
with an increased risk of developing AD, including CLU (clusterin), CR1 (complement receptor 1) 
and TREM2 (triggering receptor expressed on myeloid cells 2) (94-97). While the role of microglia in 
the neuroinflammatory response in AD is well established [reviewed in (98)], several  studies indicate 
that astrocyte-mediated inflammatory processes also contribute to neurodegeneration in AD through 
increased astrocytic expression of pro-inflammatory cytokines and chemokines, activation of the 
complement cascade, as well as reactive oxygen and nitrogen species [reviewed in ((99-101)]. 
Transcriptional analysis of GFAP+ astrocytes isolated from cortex of Alzheimer’s mice 
(APPswe/PS1dE9) reveals a proinflammatory phenotype compared to their wildtype littermates, with 
the number of genes induced and the fold-change in expression more pronounced in astrocytes than in 
microglia, suggesting that astrocytes contribute to cytokine production and play a central role in the 
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disease process. These findings were further supported by comparisons with a human AD astrocyte 
transcriptomic data set, which showed a similar alteration in inflammatory changes (102). Astrocytes 
can also suppress innate immunity through Įȕ-crystallin, suggesting that they have a modulatory 
effect on neuroinflammation. Loss of this function (through knockout of the dopamine D2 receptor) 
enhances immune responses (103). Anti-inflammatory therapies targeting astrocytes in animal models 
of AD suggest that the astrocyte contribution to neuroinflammation is a potential and relevant 
therapeutic target (104).  
 
Astrocyte hypertrophy and atrophy in Alzheimer’s disease 
Astrocyte hypertrophy has  previously been documented in Alzheimer’s disease brain (105, 106).  The 
hypertrophic response, as described earlier, is characterised typically by increased GFAP expression 
and loss of domain structure.  The CFAS neuropathology cohort is a population-based ageing brain 
(>65yrs) cohort that spans the spectrum of ageing brain pathologies. CFAS, and other population 
cohorts, allows assessment of relationships between pathology, risk factors and dementia without the 
biases inherent in pre-selection into clinical diagnostic groups [reviewed in (3, 107, 108)], providing 
complementary information to the usual case-control design. Studies in CFAS showed that the 
astrocyte hypertrophic response, characterised by GFAP expression, increases early in relation to the 
development of AD neuropathology as defined by Braak NFT stage. GFAP showed a closer 
relationship to compact than diffuse plaques. The trend for GFAP expression was the opposite of that 
for EAAT2 expression, suggesting loss of astrocyte function with AD progression. (62).  
 
Although there is some differential expression of GFAP isoforms in terms of astrocyte sub-
populations, transcript levels of most isoforms appear to increase in concert in AD and mouse AD-
models, without evidence for differential AD-related isoform changes (109, 110). However, isoform 
GFAP-İ (also designated GFAP-į) appears able to bind presenilin-1 (111), so it remains to be 
determined whether isoforms play selective functional roles in the disorder.  
 
Astrogliosis, may have functional pathological effects. Gliosis contributes to neuronal 
hyperexcitability through alterations to glutamate, GABA and chloride channels (112). Neuronal 
hyperexcitability occurs in AD, whilst in APPmt-transgenic AD models hyperexcitability is worsened 
by Aȕ immunization (113). Whether astrocytes contribute to this as a further mechanism by which 
astrocytes contribute to neuronal dysfunction is unclear at present. 
 
Whilst much of the work in human tissue has focused on hypertrophy, which is easily visualised using 
the currently available markers, there is also evidence for astrocyte atrophy.  Careful morphological 
studies in transgenic models have suggested that, in addition to gliosis, astrocytes undergo atrophy 
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particularly at early disease stages, supporting the importance of reduced function and atrophy in 
addition to hypertrophic and gain of function responses (114, 115). The fragmentation of calpain-
positive glial processes (116) and the loss of EAAT2 (62) in human tissue may be  reflections of this 
process. Loss of astrocyte processes are also seen in age related white matter lesions associated with 
serum plasma protein uptake and BBB dysfunction,  producing clasmatodendritic astrocytes (117, 
118). Astrocyte atrophy may reflect loss of function, so confining study to hypertrophic astrocytes 
identified by GFAP up-regulation may miss important changes.  
 
Oxidative stress and the DNA damage response in AD 
In addition to the hypertrophic response, there is evidence of cellular damage to astrocytes. Oxidative 
DNA damage can be found in astrocytes in the ageing brain, and is early in relation to AD stage, and 
the DNA damage response in astrocytes appears to parallel that in neurons and endothelium (119, 
120). Unrepaired DNA damage may induce senescence or apoptosis. Glia express apoptosis-related 
markers in AD, such as p53 and CD95 (121), and ȕ-galactosidase expression, a marker for 
senescence, can be found in astrocytes, although the quantitative relationship of this to AD is unclear 
(120).  
 
Astrocyte injury may contribute to loss of their function or to a proinflammatory state via the SASP, 
and a number of factors may drive this injury. Oxidative stress is likely to be important and an early 
feature of AD (122-124). Oxidative stress is also a feature of ageing in the brain (125), and indeed the 
presence of oxidative DNA damage at the earliest AD stages suggests that oxidative DNA damage in 
astrocytes may be partly related to ageing mechanisms, a further point of interaction between ageing 
and neurodegeneration. AD-related molecular pathology may also contribute to astrocyte injury; 
aggregated Aȕ can induce DNA damage and apoptosis (126, 127) and astrocytes around amyloid 
deposits in both cored and non-cored plaques express apoptosis related molecules caspase 3 and 
CD95 (128).  
 
Whilst it is clear that multiple factors may drive astrocyte pathology, related to both ageing and 
neurodegeneration, the relative partitioning of injury in vivo is uncertain. Further, different 
pathological drivers may produce different pathological molecular responses in astrocytes. So, for 
example, DNA damage but not AD pathology correlates with nuclear retention of the signalling 
molecule FOXO3a, suggesting differential effects of stressors on signalling in astrocytes (63).  
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Alterations in astrocytic signalling pathways. 
Astrocytes host a complex network of signaling pathways which are altered with the development of 
disease pathology. Indeed signalling pathways involved in orchestrating glial activation which include 
STAT3, NFțB, and MAP kinases, have previously been investigated as potential therapeutic targets 
(129).  
 
Gene expression analysis is one approach to  dissecting out molecular responses in tissue and, 
combined with laser capture microdissection, can be applied to specific cell types (130). It should be 
noted that the laser capture method will produce a sample that, whist highly enriched for the cell-type 
targeted, is not a pure sample.  Our group have previously used microarray-based gene expression 
analysis to define changes in astrocyte gene expression associated with AD progression.  Analysis 
showed down-regulation of key cellular pathways, particularly in relation to signalling, including 
insulin, IGF-1, calcium and MAP-kinase signalling (131). The protein components of the insulin and 
IGF-1 pathways are present and functional in human cultured astrocytes and can be modulated by 
insulin-fructose treatment and IGF-1R monoclonal antibody treatment respectively (132). Insulin 
regulates metabolic processes such as glycogen synthesis and proliferation in astrocytes (133). IGF-1 
signalling is important for astrocyte protection of neurons from oxidative stress (134) and interaction 
of IGF-1 and calcineurin in astrocytes has been implicated in pathogenesis in AD models (135).  
Insulin resistance is described in neurons in AD, and is a potential therapeutic target (136-139). 
Derangement of  metabolic pathways regulated by insulin and IGF-1 in astrocytes may therefore also 
contribute to impairment of astrocyte function and their support for neurons as AD progresses.   
 
Astrocyte subtypes in relation to AD pathology 
In addition to physiological subtypes, there may also be pathological heterogeneity of astrocytes 
related to their spatial relationships to specific pathological lesions. Increased gliosis with AD 
progression correlates with NFTs, but the relationship to plaques is more complex in that gliosis 
diverges from plaque burden, but glia increase in the vicinity of plaques (140).  The association of 
peri-plaque astrocytes with better cognitive preservation may suggest that the response of astrocytes 
to this lesion is neuroprotective (141). Calpain upregulation with AD progression is observed in the 
long processes of interlaminar astrocytes (116), and there are alterations in astrocytes in white matter 
in AD (142, 143). Astrocytes cannot be considered as a homogeneous population and the differential 
effects of astrocytes in these various pathological compartments is a significant question.  
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The influence of APOE on astrocyte responses. 
The mechanisms by which possession of the İ4 allele contributes to a higher risk of late-onset AD 
remain to be fully defined, but influence on astrocyte responses may be a contributory factor. 
Astrocytes respond to Aȕ in an APOE-dependent manner (144) and possession of the İ4 allele is 
associated with a lower peri-plaque astrocyte response (141). Possession of İ4 is associated with 
higher degree of GFAP expression in demented individuals (145). There may also be interaction with 
therapy. Use of non-steroidal anti-inflammatory drugs in AD is associated with lower astrocytic 
counts that is more marked in association with Ή4 (146). In a gene expression analysis of astrocytes, 
transcriptomic changes associated with AD progression were seen at earlier Braak NFT stage in 
association with İ4 allele possession, although this was a subsidiary analysis of the study based on 
few cases (131). Overall, however, these studies suggest a picture whereby the astrocyte response is 
more detrimental in individuals with the İ4 polymorphism.   
 
Evidence for the role of astrocytes from other dementias 
The involvement of astrocytes in dementia is not restricted to Alzheimer’s disease.   Vascular 
dementia is associated with dysregulation of cerebral blood flow, blood-brain barrier breakdown and 
increased inflammation and oxidative stress (147). There is considerable overlap between vascular 
dementia and AD, with evidence of cerebral amyloid angiopathy (CAA) frequently found in AD 
brains.  CAA is the vascular accumulation of Aȕ.   Interactions of astrocytic endfeet with the 
vasculature, a critical component of the NVU, is thought to be disrupted by Aȕ, with impairment of 
vascular responses. Hence the presence of CAA is likely to disrupt the NVU and could contribute to 
reduce blood flow to the brain in AD (148).  In the ArcAȕ mouse model, which exhibits severe 
vascular pathology, there are changes in astrocytes early in the disease process.  These changes 
include retraction and swelling of astrocyte endfeet surrounding vascular Aȕ deposits and reduced 
expression of the glucose transporter GLUT1 and monocarboxylate transporter 1 (MCT1) and were 
accompanied by evidence of neurovascular uncoupling and disruption of the BBB (149). 
There is also evidence that changes in astrocytic endothelin-1 are involved in dementia associated 
with stroke.  Endothelin-1 (ET-1), a potent constrictor, is synthesized by both astrocytes and 
endothelial cells in stroke and in AD brain where it plays an important role in neurovascular reactions.  
In a study investigating the role of astrocytic ET-1 in post-stroke cognitive deficit it was found that 
astrocytic ET-1 overexpression contributed to neurodegeneration (in the GET-1 mouse model) (150).   
 
In frontotemporal dementia (FTD), there is evidence that the severity of the disease is directly 
related to the degeneration of astrocytes.  This is evidenced by an increase in astrocytes with beaded 
processes as well as apoptotic features which correlated with the degree of  neuronal loss and the 
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stage of the disease (151) and there is a suggestion that as the disease progresses unreactive, 
quiescent astrocytes become involved, further exacerbating the situation.  An earlier study 
investigating astrocytic degeneration in sporadic FTD found that degenerating astrocytes correlated 
with decreased cerebral blood flow (CBF) and that areas of significant astrogliosis corresponded to 
areas of hypoperfusion, suggesting a potential causal role for astrocytes in disturbed CBF in FTD 
(152). It should be noted that these studies preceded current molecular subclassification of the 
frontotemporal lobar degenerations (the pathological pattern that underlies FTD).   
 
Finally, astrocytic star-like inclusions, which resemble tufted astrocytic fibrillary tangles, are present 
in the brains of those with Dementia with Lewy Bodies and may contain Į-synuclein, suggesting that 
in DLB a primary degenerative process takes place in both glial cells and neurons (153, 154). 
Astrocytes may be directly affected by inclusion formation, particularly with the deposition of 
phosphorylated tau, in specific neurodegenerative disorders. These include tufted astrocytes in 
progressive supranuclear palsy, astrocytic plaques in corticobasal degeneration and globular astroglial 
inclusions in globular glial tauopathy (155).   
CONCLUSION 
So what is the involvement of astrocytes in dementia? In MND there is evidence for a central role of 
astrocytes in the disease process; the “non-cell autonomous” theory (156, 157).   Whether this applies 
to AD and other dementias is unknown, but the evidence for their cellular pathology and perturbation 
of function certainly suggests an important role. Whilst the potential dichotomy between loss of 
normal function and gain of a toxic function is well recognised, the complexity of this cell, including 
intrinsic heterogeneity and different responses in relation to different molecular and cell pathologies 
suggest that a more detailed and nuanced understanding of the variations in astrocyte responses is 
required. Given the central role of this cell in microvascular regulation and neuronal and synaptic 
support, enhancing the potential neurosupportive and neuroprotective functions of astrocytes, whilst 
inhibiting their proinflammatory injurious effects offers an additional therapeutic avenue to support 
brain function in dementia.   
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FIGURE LEGENDS 
Figure 1: Immunohistochemistry illustrating variation in immunostaining patterns for astrocyte 
markers in human cerebral cortex and white matter which showed gliosis.  Sections from an 
(anonymised) case (Braak NFT stage I) from the CFAS ageing brain cohort. The left column shows 
low power views of cortex, the centre column high power view of cortex, right column high power 
view of white matter. Variation in staining patterns with antibodies to: GFAP (A, B, C); EAAT2 (D, 
E, F); glutamine synthetase (G, H, I); ALDH1L1 (J,K,L). Note variation in relative staining of cortical 
vs white matter astrocytes.  
Figure 2: The many roles of the astrocyte: (A) Astrocytes provide energy substrates for neurons, 
primarily in the form of lactate which is converted from glucose as well as providing cholesterol to 
support neuronal function. (B) The intimate association of astrocytic processes with neuronal 
synapses enables the finely-tuned regulation of synaptic transmission. Neurotransmitters are released 
from the pre-synaptic terminal such as glutamate, noradrenaline, histamine or ACh that are capable of 
binding to post-synaptic receptors or to receptors present on the surface of astrocytic processes. This 
binding can trigger a calcium response in the astrocyte that results in the release of gliotransmitters 
such as GABA, ATP or D-serine that will regulate synaptic activity. Glutamate can also be recycled 
back to the precursor glutamine, which is released into the extracellular space and taken up by 
neurons to be resynthesised into glutamate. (C) Astrocytes couple together synaptic activity with local 
blood flow to ensure neurons have a sufficient energy supply. Prostaglandin (PG), nitric oxide (NO) 
and arachidonic acid (AA) are all released in response to changes in intracellular calcium levels, 
which causes vasoconstriction or dilation. Aquaporin 4 and K+ channels are also present to maintain 
osmotic balance and for spatial K+ buffering, respectively. (D). Gap junctions such as connexin 43 
enable dialogue between neighbouring astrocytes, which is mediated by intracellular changes in 
calcium levels.  
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